BioStem Technologies, Inc.

BSEM Healthcare Biotechnology

Revenue
−28.0%
EPS
−86,766.7%

Quarter to June 2026, against a year earlier

1.13 0.09 +8.65%
Market cap
$19.4M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23
Revenue
47.48 301.83 16.69
Revenue Growth
(84.27%) 1,708.97% —
Gross Profit
47.48 301.83 16.69
Operating Income
47.48 301.83 16.69
EBT
47.48 301.83 16.69
Income after Tax
47.48 301.83 16.69
Net Income Common
(6.58) 31.88 (7.86)
EPS (Diluted)
(0.39) 1.47 (0.57)
Shares (Diluted, Weighted)
16.73 21.70 13.71
Gross Margin
100.00% 100.00% 100.00%
EBIT Margin
100.00% 100.00% 100.00%
Net Profit Margin
(13.86%) 10.56% (47.13%)
Free Cash Flow Margin
0.00% 0.00% 0.00%
EBITDA
47.48 301.83 16.69
EBIT
47.48 301.83 16.69

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 2 Nov 2026